Tennessee Oncology - Nashville; The Sarah Cannon Research Institute
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bendell, Johanna
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
KEYNOTE A60, NCT04332653: NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Active, not recruiting
1/2
215
US
NT-I7, Efineptakin alfa, rhIL-7-hyFc, pembrolizumab (KEYTRUDA®), KEYTRUDA®
NeoImmuneTech, Merck Sharp & Dohme LLC
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
11/24
12/24
NCT02740985: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Hourglass Jul 2018 - Dec 2018 : For advanced solid tumours
Completed
1
313
US
AZD4635, Durvalumab, MEDI4736, Abiraterone Acetate, Zytiga, Enzalutamide, Xtandi, Oleclumab, MEDI9447, Docetaxel, Taxotere
AstraZeneca
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
12/20
03/23

Download Options